Lupin stock gains on EIR from USFDA, but not out of the woods yet

Lupin has had a number of positive triggers over the past couple of weeks, both on the product approval and regulatory fronts. While approvals will help it launch its drugs in the US market, clearance for its various units removes a potential overhang. The company received the Establishment Investigation Report (EIR) from the US Food and Drug Administration (USFDA for the successful inspection of its Pithampur, Unit-I, at Indore, carried out last year. The Unit-II of the same plant also received regulatory clearance from the Canadian regulator. In addition to the Pithampur unit, the UK drug regulator has completed inspection